BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 19764992)

  • 1. Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response.
    de Viron E; Knoops L; Connerotte T; Smal C; Michaux L; Saussoy P; Vannuffel P; Beert E; Vekemans MC; Hermans C; Bontemps F; Van Den Neste E
    Br J Haematol; 2009 Dec; 147(5):641-52. PubMed ID: 19764992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs.
    Morabito F; Filangeri M; Callea I; Sculli G; Callea V; Fracchiolla NS; Neri A; Brugiatelli M
    Haematologica; 1997; 82(1):16-20. PubMed ID: 9107076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.
    Pettitt AR; Sherrington PD; Cawley JC
    Cancer Res; 2000 Aug; 60(15):4187-93. PubMed ID: 10945628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
    Cejkova S; Rocnova L; Potesil D; Smardova J; Novakova V; Chumchalova J; Zezulkova D; Borsky M; Doubek M; Brychtova Y; Pospisilova S; Klabusay M; Mayer J; Trbusek M
    Eur J Haematol; 2009 Feb; 82(2):133-42. PubMed ID: 19018867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA-PK, ATM and MDR proteins inhibitors in overcoming fludarabine resistance in CLL cells.
    Svirnovski AI; Serhiyenka TF; Kustanovich AM; Khlebko PV; Fedosenko VV; Taras IB; Bakun AV
    Exp Oncol; 2010 Dec; 32(4):258-62. PubMed ID: 21270755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
    Aleskog A; Tobin G; Laurell A; Thunberg U; Lindhagen E; Roos G; Nilsson K; Nygren P; Sundström C; Höglund M; Larsson R; Rosenquist R
    Eur J Haematol; 2004 Dec; 73(6):407-11. PubMed ID: 15522062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes.
    Jones GG; Reaper PM; Pettitt AR; Sherrington PD
    Oncogene; 2004 Mar; 23(10):1911-21. PubMed ID: 14755251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line.
    Månsson E; Spasokoukotskaja T; Sällström J; Eriksson S; Albertioni F
    Cancer Res; 1999 Dec; 59(23):5956-63. PubMed ID: 10606241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
    Nahi H; Selivanova G; Lehmann S; Möllgård L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
    Br J Haematol; 2008 May; 141(4):445-53. PubMed ID: 18341636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia.
    Willmore E; Elliott SL; Mainou-Fowler T; Summerfield GP; Jackson GH; O'Neill F; Lowe C; Carter A; Harris R; Pettitt AR; Cano-Soumillac C; Griffin RJ; Cowell IG; Austin CA; Durkacz BW
    Clin Cancer Res; 2008 Jun; 14(12):3984-92. PubMed ID: 18559621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells.
    Bouzar AB; Boxus M; Defoiche J; Berchem G; Macallan D; Pettengell R; Willis F; Burny A; Lagneaux L; Bron D; Chatelain B; Chatelain C; Willems L
    Br J Haematol; 2009 Jan; 144(1):41-52. PubMed ID: 19006566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features.
    Morabito F; Stelitano C; Callea I; Filangeri M; Oliva B; Sculli G; Callea V; Nobile F; Brugiatelli M
    Haematologica; 1996; 81(3):224-31. PubMed ID: 8767527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
    Bosanquet AG; Sturm I; Wieder T; Essmann F; Bosanquet MI; Head DJ; Dörken B; Daniel PT
    Leukemia; 2002 Jun; 16(6):1035-44. PubMed ID: 12040435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia.
    Lotfi K; Karlsson K; Fyrberg A; Juliusson G; Jonsson V; Peterson C; Eriksson S; Albertioni F
    Biochem Pharmacol; 2006 Mar; 71(6):882-90. PubMed ID: 16436271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
    Pepper C; Lowe H; Fegan C; Thurieau C; Thurston DE; Hartley JA; Delavault P
    Br J Cancer; 2007 Jul; 97(2):253-9. PubMed ID: 17579621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia.
    Elliott SL; Crawford C; Mulligan E; Summerfield G; Newton P; Wallis J; Mainou-Fowler T; Evans P; Bedwell C; Durkacz BW; Willmore E
    Br J Haematol; 2011 Jan; 152(1):61-71. PubMed ID: 21083655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
    Pepper CJ; Hambly RM; Fegan CD; Delavault P; Thurston DE
    Cancer Res; 2004 Sep; 64(18):6750-5. PubMed ID: 15374993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia.
    McElligott AM; Maginn EN; Greene LM; McGuckin S; Hayat A; Browne PV; Butini S; Campiani G; Catherwood MA; Vandenberghe E; Williams DC; Zisterer DM; Lawler M
    Cancer Res; 2009 Nov; 69(21):8366-75. PubMed ID: 19826055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD154 expression triggered by purine analogues in vitro: Correlation with treatment response and autoimmune events in chronic lymphocytic leukemia.
    Citores MJ; Castejon R; Villarreal M; Rosado S; Garcia-Marco JA; Vargas JA
    Exp Hematol; 2010 Mar; 38(3):165-73. PubMed ID: 20026377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.
    Secchiero P; Corallini F; Barbarotto E; Melloni E; di Iasio MG; Tiribelli M; Zauli G
    J Cell Physiol; 2006 Apr; 207(1):158-64. PubMed ID: 16270354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.